Oncology (all articles)
Perspective | N-of-1 trials in cancer drug development
26 Apr, 2023 | 14:06h | UTCN-of-1 Trials in Cancer Drug Development – Cancer Discovery
Commentary on Twitter
⭐️Just published in @AACR 's highest impact journal Cancer Discovery this week for your #FridayMotivation –> "N-of-1 Trials in Cancer Drug Development"
We propose N-of-1 trials as a departure from the traditional “drug-centric” model to a “patient-centric” model.
N-of-1 trials… pic.twitter.com/Set2jTpTBO— Vivek Subbiah, MD (@VivekSubbiah) April 21, 2023
RCT | Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer
26 Apr, 2023 | 13:57h | UTCTrastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)
RCT | Endosonography with or without confirmatory mediastinoscopy for resectable lung cancer
26 Apr, 2023 | 13:56h | UTC
ASCO Guideline Update | Venous thromboembolism prophylaxis and treatment in patients with cancer
25 Apr, 2023 | 14:49h | UTC
Review | Risk stratification of low-risk prostate cancer: individualizing care in the era of active surveillance
25 Apr, 2023 | 14:35h | UTCRisk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance – Journal of Urology (free PDF for a limited period)
Related:
Low-Value Prostate-Specific Antigen Screening in Older Males – JAMA Network Open
RCT | Patient-reported outcomes 12 years after different treatments for localized prostate cancer
RCT | Localized prostate cancer treatment options have similar 15-year survival outcomes
Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life
25 Apr, 2023 | 14:34h | UTC
Cohort Study | Risk of cancer after diagnosis of cardiovascular disease
25 Apr, 2023 | 14:29h | UTCRisk of Cancer After Diagnosis of Cardiovascular Disease – CardioOncology
Commentary: New details on the link between CVD and cancer, from a study of 27M patients – Cardiovascular Business
Clinical Trial Update | Nivolumab plus Relatlimab for advanced melanoma fail to reach OS threshold despite PFS improvement
25 Apr, 2023 | 14:25h | UTCOverall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma – NEJM Evidence
Original Study: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine
Commentary on Twitter
Original Article: “Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma,” by Georgina V. Long, MD, PhD, et al. https://t.co/g5N1AYQV1I#OncoAlert #Melanoma
— NEJM Evidence (@NEJMEvidence) April 19, 2023
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
SR | Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
25 Apr, 2023 | 14:22h | UTCAngiogenesis inhibitors for the treatment of epithelial ovarian cancer – Cochrane Library
USPSTF Statement | There is insufficient evidence to guide skin cancer screening recommendations
24 Apr, 2023 | 14:07h | UTCScreening for Skin Cancer: US Preventive Services Task Force Recommendation Statement – JAMA
Evidence Report: Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials:
Patient Page: Screening and Prevention of Skin Cancer – JAMA
Author Interview: USPSTF Recommendation: Screening for Skin Cancer – JAMA
Commentary on Twitter
2023 Recommendation Statement from the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for #skincancer in adolescents and adults (I statement). https://t.co/WB6VN2r1Nv
— JAMA (@JAMA_current) April 18, 2023
Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist
24 Apr, 2023 | 13:40h | UTCImmediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist- Cancer Treatment Reviews (free for a limited period)
See Tweet from one of the authors with infographic and link to free full text here
RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer
24 Apr, 2023 | 13:41h | UTCPanitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. https://t.co/Hjh9f3fN1z #AACR23 pic.twitter.com/uZxQUkfNbB
— JAMA (@JAMA_current) April 18, 2023
RCT | Stereotactic radiosurgery vs. conventional radiotherapy for localized vertebral metastases of the spine
24 Apr, 2023 | 13:37h | UTCStereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine: Phase 3 Results of NRG Oncology/RTOG 0631 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Audio interview: Radiosurgery of Spine Metastasis—NRG/RTOG 0631 RCT Final Results – JAMA
Commentary on Twitter
Phase 3 rand trial of spinal radiosurgery vs. conventional external beam radiation therapy for pts w/spinal metastases showed radiosurgery did not significantly improve pain response at 3mo but showed feasibility that makes it widely used today. https://t.co/LvZY1nbUpS #RadOnc
— JAMA Oncology (@JAMAOnc) April 20, 2023
Guideline | Management of pheochromocytoma and paraganglioma in patients harboring germline SDHD pathogenic variants
24 Apr, 2023 | 13:32h | UTCClinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Clinical consensus guideline on the management of #phaeochromocytoma and #paraganglioma in patients harbouring germline #SDHD pathogenic variants https://t.co/PJSiZnUXga #FREE to read with registration (also FREE) pic.twitter.com/WJA5ZGsK8d
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) April 16, 2023
M-A | 5-alpha-reductase inhibitors are not associated with increased risk of mortality from prostate cancer
24 Apr, 2023 | 13:30h | UTCAssociation Between 5α-Reductase Inhibitors and Prostate Cancer Mortality: A Systematic Review and Meta-analysis – JAMA Oncology (free for a limited period)
Commentary on Twitter
Systematic review & meta-analysis drawing on 2 decades of epidemiologic literature and including data from over 3 million patients shows no significant association between use of 5-alpha reductase inhibitor use and mortality from prostate cancer. https://t.co/3l9jT1l2P9 #PCSM
— JAMA Oncology (@JAMAOnc) April 21, 2023
Cohort Study | Circulating tumor DNA methylation may enable early detection of recurrence in colorectal cancer
24 Apr, 2023 | 13:12h | UTCEarly Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation – JAMA Oncology (free for a limited period)
Editorial: Liquid Biopsy Assessment of Molecular Residual Disease in Localized Colorectal Cancer: Is It Ready for Prime Time? – JAMA Oncology (free for a limited period)
Commentary on Twitter
Cohort study of 299 pts w/stage I-III colorectal cancer, evaluating ctDNA evaluation w/methylation markers, showed ctDNA before & after surgery, after adjuvant chemo, & during longitudinal monitoring is highly associated w/recurrence. https://t.co/csHNz5kWz3 #CRCSM #GICSM
— JAMA Oncology (@JAMAOnc) April 21, 2023
Perspective | Here’s a new data point for cancer patients to consider: ‘time toxicity’
19 Apr, 2023 | 13:18h | UTCHere’s a new data point for cancer patients to consider: ‘time toxicity’ – STAT
RCT | Small benefit from pembrolizumab + gemcitabine/cisplatin vs. gemcitabine/cisplatin alone in advanced biliary tract cancer
19 Apr, 2023 | 13:10h | UTCPembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Kelley et al – Pembrolizumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966)https://t.co/ZbdRQwzSuW#gitwitter #onctwitter pic.twitter.com/PwoNAduQxK
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 18, 2023
Review | Long-term outcomes following CAR T cell therapy: what we know so far
18 Apr, 2023 | 13:12h | UTCLong-term outcomes following CAR T cell therapy: what we know so far – Nature Reviews Clinical Oncology (if the link is paywalled, try this one in PMC)
Commentary on Twitter
In a new Review now live online, Kathryn Cappell & James Kochenderfer discuss 'Long-term outcomes following CAR T cell therapy: what we know so far' https://t.co/w89HksK1Ay #ImmunoOnc #hemeonc #medonc #leusm #lymsm #MMSM pic.twitter.com/1MEKWvXcKu
— NatureRevClinOncol (@NatRevClinOncol) April 14, 2023
ASCO Guideline Update | Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer
18 Apr, 2023 | 12:54h | UTC
RCT | MRI–guided vs CT–guided stereotactic body radiotherapy for prostate cancer
18 Apr, 2023 | 12:52h | UTC
M-A | Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer
17 Apr, 2023 | 12:59h | UTC
RCT | Zolbetuximab plus mFOLFOX6 in CLDN18.2+ HER2- advanced gastric or gastro-oesophageal junction adenocarcinoma
17 Apr, 2023 | 13:00h | UTCZolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
News Release: Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet – PR Newswire
Cohort Study | Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer
17 Apr, 2023 | 12:57h | UTCCancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer – The ASCO Post